Figure 1.
![Figure 1. Percentage of patients with severe cGVHD in 3 randomized trials. (GITMO,6,7 Finke,8,9 Kröger,10 and combined data [total] are shown).](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/1/9/10.1182_bloodadvances.2016001560/3/advances001560f1.jpeg?Expires=1724259221&Signature=SXodMXZJ1oTI~6nNkBs3IPoskazL3g1lVa0codMQCoaE0c9csAT6OsTu1lD31l-DiUkpUQn0M~AhZo~12NXV0~9FKq3dx9CEK-vTF9xcoDfuzCA9GTxBf~ytElC~pdjEnEl9OlYq-g1bg8RFhyfacdw4ZAE9bV~2fvmwKP8WPrKWA0rRzqNoK7K6A82bTtmWyHDqFW25rhithWlU1V2gDfKfhjBQab09um7f7lc5dqnNAX2wGDlRhhH24jH1k3xbYYZjgozLvdvBHCavoXBKHLCsutjSV-vTK5k75c4NjSVIc6sBsShVGHmllpAkX40s-8icbhAESxt6lXls-Sx9Yw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Percentage of patients with severe cGVHD in 3 randomized trials. (GITMO,6,7 Finke,8,9 Kröger,10 and combined data [total] are shown).
Percentage of patients with severe cGVHD in 3 randomized trials. (GITMO,6,7 Finke,8,9 Kröger,10 and combined data [total] are shown).
